Phase I, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Single-Agent Pf-03758309, An Oral Pak Inhibitor, In Patients With Advanced Solid Tumors.

L. R. Mileshkin,Lee S. Rosen,T. Blumenkopf,Aurora Breazna, S. Darang, J. Davison,J. Gallo,Jonathan W. Goldman,D. D. Wang, S. Zhang,S. G. Eckhardt

JOURNAL OF CLINICAL ONCOLOGY（2011）

Cited 5|Views16

No score

Abstract

e13607^ Background: Abnormalities of the Rho family pathway are involved in different steps of malignant transformation and tumor progression. Of the many effector proteins that bind to active Rho ...

Translated text

Key words

oral pak inhibitor,pharmacokinetic,pharmacodynamic study,advanced solid tumors,dose-escalation,single-agent

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined